Nationwide Children’s Hospital spinout Celenex could fetch as much as $452m upon completion of milestones after progressing rare disease therapies conceived at the hospital’s collaborative program with Ohio State University.
Celenex, a US-based gene therapy developer spun out of Nationwide Children’s Hospital, was acquired by rare disease treatment developer Amicus Therapeutics today for an upfront cash consideration of $100m.
The spinout’s investors could receive up to $15m on the fulfilment of development milestones and up to $337m for certain regulatory and sales milestones, though Amicus expects to pay $75m at most over the next four years.
Through the acquisition, Amicus has bought development and commercial rights to ten…
